How Wegovy helps heart health: what the evidence actually shows

The trial that gave Wegovy its cardiovascular licence

The SELECT study enrolled 17,604 adults aged 45 or over, all of whom had established cardiovascular disease (previous heart attack, stroke, or peripheral arterial disease) and a BMI of at least 27, but none had type 2 diabetes. Participants were randomly assigned to semaglutide 2.4mg once weekly or a placebo injection, alongside standard care, and followed for a median of around four years.

The primary outcome was a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. The semaglutide group reached that outcome at a rate roughly 20% lower than the placebo group, a result described by investigators as statistically robust and clinically meaningful. Crucially, the benefit appeared to accumulate steadily over time rather than clustering early, which speaks to a sustained effect rather than a one-off adjustment.

The NICE appraisal of semaglutide for weight management acknowledged this wider evidence base, and the cardiovascular outcomes data have since informed regulatory thinking both in the UK and internationally. The MHRA authorised the cardiovascular-risk-reduction indication for Wegovy in the UK, making it the first GLP-1 medicine in this country licensed for that purpose in people without diabetes.

If you want to understand the full scope of what Wegovy is currently approved for, the Wegovy overview page covers both indications clearly.

Mechanisms: how semaglutide may protect the heart beyond weight loss

One of the most scientifically interesting aspects of the SELECT findings is that cardiovascular benefit emerged before participants had lost substantial weight. That timing points to effects on the heart and blood vessels that are at least partly independent of fat reduction, and researchers have proposed several pathways.

GLP-1 receptors are present in heart tissue and blood vessels, not just in the gut and brain. Activating them appears to reduce inflammatory signalling, improve the function of the inner lining of blood vessels (the endothelium), and modestly lower blood pressure and resting heart rate in many people. Semaglutide also consistently reduces LDL cholesterol and triglycerides in trial data, which are established cardiovascular risk factors.

Beyond those direct vascular effects, reducing body weight over time does lower the mechanical and metabolic burden on the heart: less visceral fat means less chronic low-grade inflammation, better insulin sensitivity, and reduced strain on the circulatory system. So the full cardiovascular benefit seen over four years in SELECT is probably a combination of these early direct effects and the longer-term consequences of meaningful weight reduction, and our page on how Wegovy helps the heart explains each of those mechanisms in more detail.

The NHS medicines page for semaglutide provides a clear patient-level summary of how the medicine works, including its effects on appetite and metabolic signals.

Who the cardiovascular indication applies to, and who it does not

The cardiovascular-risk-reduction licence is specific. It covers adults with a BMI of 27 or above who already have established cardiovascular disease and who do not have type 2 diabetes. It is not a general heart-health supplement for people without prior cardiovascular events, and it does not apply to people with type 2 diabetes, who have separate treatment pathways.

Weight management is a related but distinct indication, and one with its own BMI thresholds and eligibility criteria. Someone might qualify under one indication but not the other, which is precisely why a prescriber reviews each person's history individually rather than applying a single rule.

A comparison of semaglutide's cardiovascular evidence with its weight-management data shows how the two bodies of research overlap and where they diverge, useful context if you are trying to understand which pathway is relevant to your situation.

For context on what private treatment costs, the Wegovy price comparison page sets out the UK private market honestly, including what a legitimate prescription price should include.

Practical considerations if cardiovascular health is your reason for exploring Wegovy

If you have existing heart disease and are considering Wegovy, there are a few things worth knowing before your consultation. First, your cardiologist or GP should be part of the conversation, not because it is legally required, but because a prescriber making a safe decision for you will want to understand your current cardiac medication, any recent procedures, and your overall risk profile. GLP-1 medicines interact with some antihypertensives in terms of blood pressure lowering, and your doses of other medicines may need review.

Second, the once-weekly injection routine fits around most people's schedules without much disruption, many people pick the same morning each week, tying it to something consistent. One patient described keeping the pen in the fridge door alongside their evening medication as the simplest way to remember it.

Third, the effect on heart outcomes takes time. SELECT ran for four years. This is not a medicine you take for six weeks and assess for cardiovascular benefit; it requires sustained use alongside the lifestyle and medical management your team recommends.

Our clinical team reviews every consultation personally (a real prescriber reads your answers, not automated software) so any cardiovascular history you share is assessed carefully before a prescription is considered. Wegovy for cardiovascular risk reduction remains a prescription-only medicine, and clinical suitability is determined case by case.

You can read more about the broader evidence on Wegovy's cardiovascular benefits, and if you have questions about specific situations such as pregnancy or planning a family while on treatment, the Wegovy and pregnancy page addresses those carefully.

When you are ready to explore whether treatment is appropriate for you, starting a free consultation is the first step, there is no charge to speak with our prescribers, and the review happens the same day.